



ACC (American College of Cardiology) 2025

March 29-31, 2025; Chicago, IL; Resource Hub – Draft

---

**Welcome to our resource hub for ACC 2025!** This is a one-stop-shop for all your ACC needs. The conference will feature 300+ educational and late-breaking clinical research sessions and seven guideline-specific sessions across 11 [learning pathways](#). We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

## Table of Contents

[Useful Conference Links](#)

[Day-of Conference Reports](#)

[Diabetes Therapy Highlights](#)

[Diabetes Big Picture Highlights](#)

[Previous ACC Coverage on CCKB](#)

## Useful Conference Links

1. [Conference Website](#)
2. [Conference Registration](#)
3. [Day-by-Day Conference Preview](#)
4. [Conference Schedule; Online Program Planner](#)

## Day-of Conference Reports

1. [Day #1 Highlights](#)
2. [Day #2 Highlights](#)

## Diabetes Therapy Highlights

1. [Full results of SOUL trial](#): Dr. Darren McGuire presents the superiority of oral semaglutide in cardiovascular events
2. [Retrospective analysis shows Lilly’s tirzepatide \(Mounjaro\)](#) improves cardiovascular outcomes substantially in people with T2D and HF<sub>r</sub>EF
3. [GLP-1 RAs in heart failure](#): Is it all about weight loss?
4. [Meta-analysis suggests empagliflozin and dapagliflozin](#) have comparable cardiovascular efficacy in patients with T2D
5. [Full results of STRIDE trial](#): Semaglutide improves maximum walking distance by 13% (+40 meters) and adverse clinical outcomes by 54% in people with T2D and peripheral artery disease
6. [Diagnosis, treatment, and clinical considerations of HFpEF](#): Sarcopenia as a potential risk of GLP-1 RA use in older patients
7. [Lipid management](#) through risk assessment, prevention, and therapies
8. [Dr. Steven Nissen presents full results of phase 2 ALPACA trial](#): siRNA lepodisiran reduces Lp(a) by 94% at six months

9. [“The cardiometabolic jackpot”](#): Evidence-based dietary strategies and pharmacotherapies for durable weight loss
10. [Comprehensive overview of key updates](#), clinical evidence, and clinical pearls of GLP-1 RAs in obesity
11. [Systematic meta-analysis suggests SGLT-2 inhibitors may reduce atrial fibrillation](#) risk in people with T2D compared to GLP-1 RAs
12. [Cardiovascular risk management in people with cardio-kidney-metabolic syndrome](#): GLP-1 RAs, SGLT-2 inhibitors, and finerenone
13. [The efficacy of GLP-1 RAs in women](#): Sex-based risk factors and key considerations
14. [Universal screening?](#) Lively debates on coronary artery calcium scan and Lp(a) testing for CV risk stratification

### **Diabetes Big Picture Highlights**

1. [“The threshold where history and opportunity converge”](#): ACC President Dr. Cathleen Biga on the role of innovation, quality, and equity in transformative care
2. [Preview of the Exhibit Hall](#): More than 280 booths offering insights on therapies and technologies for heart health

### **Previous ACC Coverage on CCKB**

1. [ACC 2024 Full Report](#)
2. [ACC 2023 Full Report](#)
3. [ACC 2022 Full Report](#)
4. [ACC 2021 Full Report](#)
5. [ACC 2020 Full Report](#)
6. [ACC 2019 Full Report](#)
7. [ACC 2018 Full Report](#)
8. [ACC 2017 Full Report](#)
9. [ACC 2016 Full Report](#)